Literature DB >> 1530767

Effect of omega 3 and omega 6 fatty acids on transformation of cultured cells by irradiation and transfection.

M Takahashi1, M Przetakiewicz, A Ong, C Borek, J M Lowenstein.   

Abstract

Mouse embryo fibroblasts (C3H 10T1/2) were exposed to 4 Gy of gamma-rays. The cells yielded 5-8 transformed foci per 10(4) surviving cells. Addition of 100 microM of either eicosapentaenoate or docosahexaenoate to the tissue culture medium reduced the number of transformed foci to 0-1.4. C3H 10T1/2 and NIH 3T3 cells were transfected with plasmid T24 containing the Harvey ras oncogene. C3H 10T1/2 cells yielded 0.85-1.1 foci/ng DNA, while NIH 3T3 cells yielded 0.12-0.14 foci/ng DNA. Foci formation was suppressed 65% in C3H 10T1/2 cells and 93% in NIH 3T3 cells when 100 microM eicosapentaenoate was present in the culture medium. Docosahexaenoate had a similar but somewhat weaker effect. Addition of arachidonate to the medium had little or no effect. Cells grown in the presence of added eicosapentaenoate or docosahexaenoate produced much less prostaglandin E when challenged with calcium ionophore A23187. This is a reflection of changes in arachidonate production or utilization that occur during transformation which are suppressed by the added omega 3 fatty acids. Addition of eicosapentaenoate or docosahexaenoate to the culture medium resulted in extensive remodeling of the molecular species of the four major phospholipid classes that were examined. In its simplest form, omega 3-fatty acid-containing species substantially replaced omega 6-fatty acid-containing species. However, many more subtle changes occurred, and the different phospholipids responded differently to different polyunsaturated fatty acids. A feature of C3H 10T1/2 cells was their preferential accumulation of molecular species of 22-carbon fatty acids such as docosapentaenoate (22:5 omega 3) and docosatetraenoate (22:4 omega 6) in preference to eicosapentaenoate (20:5 omega 3) and eicosapentaenoate (arachidonate, 20:4 omega 6). It is proposed that the protective effect of eicosapentaenoate and docosahexaenoate arises out of the changes in the composition of the fatty acids that are released from one or more phospholipids by the action of phospholipases. The changes consist of a reduced release of arachidonate, the normal substrate of cyclooxygenase and lipoxygenases, and a greatly increased release of eicosapentaenoate and docosahexaenoate, which inhibit one or more of these enzymes, or form oxygenated products which are not as active as the arachidonate-derived products. Other mechanisms are also considered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530767

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Diet and the prevention of cancer. Author's recommendations are not justified.

Authors:  U Gonder
Journal:  BMJ       Date:  1999-07-17

2.  Omega-3 and omega-6 fatty acid intakes and endometrial cancer risk in a population-based case-control study.

Authors:  Hannah Arem; Marian L Neuhouser; Melinda L Irwin; Brenda Cartmel; Lingeng Lu; Harvey Risch; Susan T Mayne; Herbert Yu
Journal:  Eur J Nutr       Date:  2012-08-23       Impact factor: 5.614

3.  An extended method for separating and quantitating molecular species of phospholipids.

Authors:  M G Wiley; M Przetakiewicz; M Takahashi; J M Lowenstein
Journal:  Lipids       Date:  1992-04       Impact factor: 1.880

Review 4.  Improved biochemical strategies for targeted delivery of taxoids.

Authors:  Thota Ganesh
Journal:  Bioorg Med Chem       Date:  2007-03-18       Impact factor: 3.641

5.  Dietary modulation of DNA adduct formation of the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline in the male Fischer 344 rat.

Authors:  H A Schut
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

Review 6.  Molecular mechanisms in cancer induction and prevention.

Authors:  C Borek
Journal:  Environ Health Perspect       Date:  1993-10       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.